Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 1617-1627, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kicman, A. T.
Right arrow Articles by Cowan, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kicman, A. T.
Right arrow Articles by Cowan, D. A.

Clinical Chemistry, Vol 41, 1617-1627, Copyright © 1995 by American Association for Clinical Chemistry

Proposed confirmatory procedure for detecting 5 alpha- dihydrotestosterone doping in male athletes

AT Kicman, SB Coutts, CJ Walker and DA Cowan
Drug Control Centre, King's College London, UK.

Currently, there is no recommended confirmatory procedure for detecting doping with the anabolic steroid 5 alpha-dihydrotestosterone (DHT) in sportsmen. To develop a method, we determined ratios of hormone concentrations in urine from 120 healthy men and used these to set discrimination limits. These limits were then applied to results for urine specimens from 10 volunteers given DHT percutaneously (125 mg twice daily for 4 days). The ratio of DHT to epitestosterone (EpiT) was chosen as the primary marker of DHT administration, and ratios of 5 alpha-androstane-3 alpha, 17 beta-diol (5 alpha-ADIOL) to EpiT, 5 alpha- ADIOL to luteinizing hormone, and 5 alpha-ADIOL to 5 beta-androstane-3 alpha, 17 beta-diol were proposed as secondary markers. To evaluate method suitability, we analyzed 194 samples from sports competitors; results for 193 samples were negative, but the ratios in 1 sample greatly exceeded all the chosen limits. In conclusion, we propose that a test scheme based on our recommendations be considered for implementation in all Olympic drug-testing laboratories.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
T. Bassindale, D. A. Cowan, S. Dale, A. J. Hutt, A. R. Leeds, M. J. Wheeler, and A. T. Kicman
Effects of Oral Administration of Androstenedione on Plasma Androgens in Young Women Using Hormonal Contraception
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6030 - 6038.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
B.M. Brady, M. Walton, N. Hollow, A.T. Kicman, D.T. Baird, and R.A. Anderson
Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception
Hum. Reprod., November 1, 2004; 19(11): 2658 - 2667.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. T. Kicman, T. Bassindale, D. A. Cowan, S. Dale, A. J. Hutt, and A. R. Leeds
Effect of Androstenedione Ingestion on Plasma Testosterone in Young Women; a Dietary Supplement with Potential Health Risks
Clin. Chem., January 1, 2003; 49(1): 167 - 169.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. T. Kicman, J. K. Fallon, D. A. Cowan, C. Walker, S. Easmon, and D. Mackintosh
Candida albicans in Urine Can Produce Testosterone: Impact on the Testosterone/Epitestosterone Sports Drug Test
Clin. Chem., October 1, 2002; 48(10): 1799 - 1801.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. B. Coutts, A. T. Kicman, D. T. Hurst, and D. A. Cowan
Intramuscular administration of 5{alpha}-dihydrotestosterone heptanoate: changes in urinary hormone profile
Clin. Chem., November 1, 1997; 43(11): 2091 - 2098.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.